AR062477A1 - Formulacion aerosol para la inhalacion de beta - agonistas - Google Patents

Formulacion aerosol para la inhalacion de beta - agonistas

Info

Publication number
AR062477A1
AR062477A1 ARP070103722A ARP070103722A AR062477A1 AR 062477 A1 AR062477 A1 AR 062477A1 AR P070103722 A ARP070103722 A AR P070103722A AR P070103722 A ARP070103722 A AR P070103722A AR 062477 A1 AR062477 A1 AR 062477A1
Authority
AR
Argentina
Prior art keywords
alkyl
inhalation
aerosol formulation
agonists
beta
Prior art date
Application number
ARP070103722A
Other languages
English (en)
Inventor
Michael Nowak
Michael Aven
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062477(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR062477A1 publication Critical patent/AR062477A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulacion aerosol exenta de gas propulsor, para la inhalacion, la cual contiene uno o varios compuestos de la formula general 1 en la que los radicales R1, R2, R3 y X- pueden tener los significados mencionados en las reivindicaciones y en la descripcion. Reivindicacion 1: Formulacion medicamentosa que contiene como unico principio activo uno o varios compuestos de la formula general 1 en la que significan R1 y R2 iguales o diferentes, hidrogeno, halogeno, alquilo C1-4 o conjuntamente alquileno C1-6 y R3 hidrogeno, halogeno, OH, alquilo C1-4 u O-alquilo C1-4; X- un anion cargado multiples veces negativamente, eventualmente en forma de sus tautomeros, enantiomeros, mezclas de los enantiomeros, racematos o solvatos, al menos un ácido farmacologicamente tolerable, eventualmente otros coadyuvantes y/o formadores de complejos, farmacologicos tolerables y, como disolvente, agua, etanol o una mezcla de agua y etanol.
ARP070103722A 2006-08-22 2007-08-22 Formulacion aerosol para la inhalacion de beta - agonistas AR062477A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119274 2006-08-22

Publications (1)

Publication Number Publication Date
AR062477A1 true AR062477A1 (es) 2008-11-12

Family

ID=38564599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103722A AR062477A1 (es) 2006-08-22 2007-08-22 Formulacion aerosol para la inhalacion de beta - agonistas

Country Status (9)

Country Link
US (1) US20080053430A1 (es)
EP (1) EP2056837A1 (es)
JP (1) JP2010501523A (es)
AR (1) AR062477A1 (es)
CA (1) CA2661442A1 (es)
PE (1) PE20080425A1 (es)
TW (1) TW200820974A (es)
UY (1) UY30555A1 (es)
WO (1) WO2008023005A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
US8521494B2 (en) * 2009-03-24 2013-08-27 Chevron U.S.A. Inc. System and method for characterizing fractures in a subsurface reservoir

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026534A1 (de) * 1980-07-12 1982-03-18 C.H. Boehringer Sohn, 6507 Ingelheim 3,1-benzoxazin-2-one, ihre herstellung und verwendung
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos

Also Published As

Publication number Publication date
JP2010501523A (ja) 2010-01-21
PE20080425A1 (es) 2008-06-16
TW200820974A (en) 2008-05-16
WO2008023005A1 (de) 2008-02-28
CA2661442A1 (en) 2008-02-28
UY30555A1 (es) 2008-03-31
EP2056837A1 (de) 2009-05-13
US20080053430A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
ECSP088294A (es) Formulación en aerosol para la inhalación de beta-agonistas
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
DOP2010000191A (es) Derivados bis-(sulfonilamino)
CO6170341A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
UY30327A1 (es) Nuevos compuestos ii
AR062477A1 (es) Formulacion aerosol para la inhalacion de beta - agonistas
GB201201744D0 (en) Novel compounds
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
MX2009013626A (es) DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE.
CR9268A (es) Nuevo derivado de diazabiciclononeno
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP067004A (es) Formulación en aerosol para la inhalación de beta-agonistas
UY29749A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
AR075235A1 (es) Derivados de indol como agentes anticancer.
BR112012007179B8 (pt) composto inibidor da di-hidro-orotato desidrogenase, e, formulação farmacêutica
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
AR065872A1 (es) Derivados de benzimidazol sustituidos con heterociclos,composiciones farmaceuticas que los contienen,proceso para prepararlos y sus usos en trastornos de ansiedad, trastornos depresivos y enfermedades de alzheimer, entre otros.
CO6150168A2 (es) Combinaciones farmacologicas que comprenden benzoxazinonas para el tratamiento de enfermedades de las vias aereas
NO20081587L (no) Aerosolformulering for inhalering
AR054584A1 (es) Inhibidores de la bomba de protones isotopicamente sustituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal